Neuland Labs Q3FY26 Investor Presentation Highlights
Neuland Laboratories reported Q3FY26 Total Income of ₹447.8 crore (up 11.4% YoY), but PAT declined 60% YoY to ₹40.4 crore. EBITDA was ₹85 crore, with margins at 19.0%. For 9MFY26, Total Income was ₹1264.4 crore, and PAT was ₹150.6 crore. The company approved moving its R&D to a 140k sq ft facility and had a Capex outflow of ₹254 crore in 9MFY26.
The financial results show a notable decrease in profitability (PAT) despite revenue growth, which could impact investor sentiment. However, the company's strategic initiatives, R&D facility expansion, and positive outlook on business momentum suggest medium-term potential.
The company reported revenue growth but a significant decline in PAT and subdued EBITDA margins, indicating mixed financial performance. Management commentary points to strategic investments and future opportunities, balancing the current financial results.
Neuland Laboratories Limited has released an investor presentation for the quarter and nine months ended December 31, 2025 (Q3FY26 & 9MFY26).
The company reported Total Income for Q3FY26 at ₹447.8 crore, a 11.4% year-on-year increase. However, EBITDA for the quarter stood at ₹85 crore, a 6% YoY decrease, with EBITDA margins declining by 350 bps to 19.0%. Profit After Tax (PAT) saw a significant decrease of 60% YoY to ₹40.4 crore. For the nine months ended December 31, 2025 (9MFY26), Total Income was ₹1264.4 crore (8.9% YoY growth), while EBITDA was ₹284.0 crore (-0.2% YoY), and PAT was ₹150.6 crore (-35% YoY).
Management commentary highlighted that revenues were in line with the outlook, but subdued EBITDA margins were due to product mix and increased operating expenses. The company continues to see good momentum and is making investments for long-term growth opportunities. There is increasing interest from customers for Neuland's capabilities as a proven commercial NCE drug substance manufacturer. Investments are leading to more engagements with existing customers and attracting new ones. The CMS revenues are driven by commercial molecules, with growth expected from new project orders and traction from Innovators with peptide molecules in the pipeline. In the GDS segment, Ezetimibe and Mirtazapine were key molecules, with Ezetimibe expected to drive growth. The Specialty business was subdued, with revenue driven by Apixaban and Dorzolamide.
Financial highlights include working capital days of sale at 145 days in Q3FY26, down from 155 days in Q2FY26. The company has received Board approval for R&D to move to a leased facility of 140,000 sq ft at Genome Valley. Capex outflow in 9MFY26 was ₹254 crore. Net Debt stood at ₹(-202.6) crore as at Q3FY26 end.
The presentation also detailed the company's business strategy, focusing on a steady shift from low margin Prime to high margin Specialty and CMS segments. Neuland's businesses include Generic APIs (GDS) and Custom Manufacturing Solutions (CMS), with a total reactor volume of 12,18,000 liters and approximately 2131 employees, including 428 scientists in R&D. The company has 3 cGMP manufacturing facilities and expertise in various complex chemical processes. Globally, Neuland serves customers in over 80 countries, with 89% of revenue from exports.
The presentation noted that FY25 revenues showed a slight decline due to the natural lifecycle of projects in the CMS business. Historical data indicated fluctuations in EBITDA margins due to raw material price spikes and capacity utilization. The company is focused on building a sustainable supply chain and digitalization.
What to do with a filing like this
Neuland Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neuland Laboratories Limited. Read the original for the full detail.